Health Condition 1: N428- Other specified disorders of prostate
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Control Intervention2: NIL: NIL
Sponsors
Pfizer Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. New diagnosis of mCRPC during the case selection window (between 15 April 2019 to 14 January 2022, inclusive). mCRPC is defined as the current and/or historical presence of metastases on any imaging modality with evidence of disease progression (a rising PSA or radiographic progression (as defined by the investigator) despite ongoing castration therapy [LHRH agonist / antagonist or prior surgical orchiectomy]). 2. Aged at least 18 years upon diagnosis of mCRPC. Of note, patients may be alive or deceased at the date of data abstraction.
Exclusion criteria
Exclusion criteria: Previously enrolled in an interventional trial related to CRPC (patients may have been enrolled in trials of primary treatment and/or hormone-sensitive prostate cancer).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe demographic and clinical characteristics at first diagnosis of mCRPC. Document treatment patterns from original prostate cancer diagnosis leading up to, upon and following diagnosis of mCRPC. Assess clinical outcomes among patients diagnosed with mCRPC, including prostate-specific antigen (PSA) response, real-world progression-free survival (PFS), real-world objective response rate (ORR), OS, and death by treatment lines. Report mCRPC-specific HCRU where applicable Document time on treatment for each line of treatment for mCRPC Document time to next treatment from initiation of a systemic therapy line to the commencement of the subsequent systemic therapy line for mCRPC Document time to subsequent chemotherapy from initiation of first-line systemic treatment for mCRPCTimepoint: 24 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
Argentina, Brazil, India, Saudi Arabia, Taiwan, Turkey, United Arab Emirates
Contacts
Public ContactAntara Chaudhri
Pfizer Limited
Outcome results
None listed